Amphastar Pharmaceuticals, Inc. Q2 2025 Earnings Recap

AMPH Q2 2025 August 8, 2025

Get alerts when AMPH reports next quarter

Amphastar Pharmaceuticals reported Q2 2025 net revenues of $174.4 million, driven by robust sales of BAQSIMI, which jumped 21% year-over-year, underscoring the strength of its diversified portfolio.

Earnings Per Share Beat

$0.85 vs $0.71 est.

+19.7% surprise

Revenue Miss

174414000 vs 177100000 est.

-1.5% surprise

Market Reaction

1-Day -0.89%

5-Day -0.49%

30-Day -4.0%

See AMPH alongside your other holdings

Add to your portfolio — free

Key Takeaways

BAQSIMI recorded its highest quarterly sales at $46.7 million, marking a 21% increase from the prior year.
Total revenues decreased 4% due to heightened competition in legacy products, yet steady performance in Primatene MIST indicated resilient consumer demand.
Amphastar announced a significant expansion of its California manufacturing facility, aimed at quadrupling domestic capacity to strengthen supply chain resilience.
The company remains optimistic about regulatory approvals, particularly for its AMP-002 and AMP-015 product candidates, with key GDUFA dates approaching.
Continued investment in R&D is a priority, with expenses rising 14% year-over-year to support future growth initiatives.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit AMPH on AllInvestView.

Next Q3 2025